NEWRON PHARMACEUT. EO-20 (NP5) — Capital Reinvestment Ratio
Latest as of June 2025:
0.00x
NEWRON PHARMACEUT. EO-20 (NP5) has a Capital Reinvestment Ratio of 0.00x as of June 2025, meaning it reinvests 0% of its operating cash flow (€33.60 Million) in capital expenditures (€31.00K). See NEWRON PHARMACEUT. EO-20 (NP5) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
€33.60 Million
EUR
Capital Expenditures
€31.00K
EUR
Data as of
Jun 2025
Most recent filing
NEWRON PHARMACEUT. EO-20 Capital Reinvestment Ratio (2012–2025)
This chart tracks NEWRON PHARMACEUT. EO-20's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for NEWRON PHARMACEUT. EO-20 (2012–2025)
Year-by-year Capital Reinvestment Ratio for NEWRON PHARMACEUT. EO-20 from 2012 to 2025. For live market cap and broader valuation context, see NEWRON PHARMACEUT. EO-20 (NP5) total market value.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | €32.56 Million | €47.31K | ▼ -23.1% |
| 2012 | 0.00x | €5.83 Million | €11.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow